Swiss pharmaceutical company Actelion Ltd Monday said a study of its brain artery drug clazosentan showed that more time is needed to determine whether the product is effective, in a major setback that sent the shares sharply lower.
Therapeutics Daily
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Matrix Surgical’s OmniPore Implants Cleared for Marketing
The company expects to launch additional variants in early 2019.
AbbVie, Novartis Reach Deal on Humira Biosimilar
AbbVie reported Humira sales of $18.4 billion in 2017.